Fig. 5

Performance of NLR and lactate in predicting short-term mortality risk was compared in 290 patients with HBV-ACLF in the derivation cohort. a Receiver operating characteristics (ROC) curve analyses for 28-day mortality risk in non-cirrhotic (n = 67) or cirrhotic subgroup (n = 223); b ROC analyses for 90-day mortality risk in the above-mentioned two subgroups; c Kaplan–Meier analyses for 90-day survival based on three risk levels of baseline lactate; d KM analyses for 90-day survival based on three risk levels of baseline NLR. Lactate was graded into three risk levels (< 1.5 mmol/L, 1.5–2.5 mmol/L, and > 2.5 mmol/L) according to the AARC ACLF score. NLR was divided into three risk levels (< 3.10, 3.10–4.78, and > 4.78) based on the upper limit of normal and the optimal cut-off value evaluated in the sensitivity analyses in the derivation cohort. The Hanley & McNeil method was used for AUROC comparisons. Abbreviations: NLR, neutrophil-to-lymphocyte ratio; ACLF, acute-on-chronic liver failure; HBV-ACLF, hepatitis b related ACLF; AARC, Asian Pacific Society for the Study of the Liver ACLF research consortium